181 related articles for article (PubMed ID: 36318865)
21. Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting.
Garrido D; Bove V; Villano F; Riva E
Acta Medica (Hradec Kralove); 2023; 66(3):117-121. PubMed ID: 38511422
[TBL] [Abstract][Full Text] [Related]
22. Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Franke N; Winter A; Tiedemann R; Kukreti V
Leuk Lymphoma; 2015; 56(9):2668-73. PubMed ID: 25573201
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
24. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
Waszczuk-Gajda A; Gras L; de Wreede LC; Sirait T; Illes A; Ozkurt ZN; Snowden JA; Arat M; Bulabois CE; Niederland J; Sever M; Paneesha S; Potter V; Gadisseur A; Chalopin T; Van Gorkom G; López JM; Kerre T; Drozd-Sokolowska J; Raj K; Hayden PJ; Beksac M; Yakoub-Agha I; McLornan DP; Schönland S
Bone Marrow Transplant; 2023 Apr; 58(4):424-429. PubMed ID: 36681775
[TBL] [Abstract][Full Text] [Related]
25. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
[TBL] [Abstract][Full Text] [Related]
26. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On
Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908
[TBL] [Abstract][Full Text] [Related]
27. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma.
Davis JA; Thurlapati A; Weeda E; Gaffney KJ; Smith D; Maldonado A; Granger K; Martin KE; Williams YM; Herrington T; Velayati A; Bakos JK; Green K; Hashmi H
Ann Hematol; 2024 Jan; 103(1):251-258. PubMed ID: 37851073
[TBL] [Abstract][Full Text] [Related]
28. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
29. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant.
Karam D; Gertz M; Lacy M; Dispenzieri A; Hayman S; Dingli D; Buadi F; Kapoor P; Kourelis T; Warsame R; Hogan W; Kumar S
Bone Marrow Transplant; 2022 May; 57(5):803-809. PubMed ID: 35297404
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
31. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
[TBL] [Abstract][Full Text] [Related]
32. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
33. Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine.
Shimazu Y; Mizuno S; Fuchida SI; Suzuki K; Tsukada N; Hanagaishi A; Itagaki M; Kataoka K; Kako S; Sakaida E; Yoshioka S; Iida S; Doki N; Oyake T; Ichinohe T; Kanda Y; Astuta Y; Takamatsu H;
Cancer Sci; 2021 Dec; 112(12):5034-5045. PubMed ID: 34644446
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
[TBL] [Abstract][Full Text] [Related]
35. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
[TBL] [Abstract][Full Text] [Related]
36. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
37. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
38. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
39. Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels.
Eicher F; Mansouri Taleghani B; Schild C; Bacher U; Pabst T
Hematol Oncol; 2020 Oct; 38(4):523-530. PubMed ID: 32594534
[TBL] [Abstract][Full Text] [Related]
40. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
Merz M; Neben K; Raab MS; Sauer S; Egerer G; Hundemer M; Hose D; Kunz C; Heiß C; Ho AD; Goldschmidt H; Hillengass J
Ann Oncol; 2014 Jan; 25(1):189-95. PubMed ID: 24356629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]